• LAST PRICE
    2.9000
  • TODAY'S CHANGE (%)
    Trending Down-0.1300 (-4.2904%)
  • Bid / Lots
    2.9000/ 2
  • Ask / Lots
    2.9500/ 8
  • Open / Previous Close
    3.1000 / 3.0300
  • Day Range
    Low 2.8400
    High 3.1000
  • 52 Week Range
    Low 0.1700
    High 9.7700
  • Volume
    569,225
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.03
TimeVolumeTPST
09:32 ET35233.05
09:34 ET1003.08
09:36 ET17003.0497
09:38 ET28783.02
09:39 ET6003.05
09:41 ET13963.04
09:43 ET15003.03
09:45 ET36943.03
09:48 ET35003.04
09:50 ET66003.0597
09:54 ET1753.06
09:56 ET1753.035
09:57 ET111893
09:59 ET11503.02
10:01 ET28003.01
10:03 ET18003
10:06 ET1483.0289
10:12 ET5003.0199
10:14 ET323543.03
10:15 ET236212.99
10:17 ET21082.99
10:19 ET9202.98
10:21 ET17522.98
10:24 ET296202.94
10:26 ET18632.93
10:28 ET4382.948
10:30 ET262582.92
10:32 ET3202.9501
10:33 ET11002.954
10:35 ET1002.93
10:39 ET16002.9438
10:44 ET68542.95
10:46 ET1002.97
10:50 ET5832.95
10:51 ET8502.946
10:55 ET38482.96
10:57 ET10002.958
11:02 ET13522.96
11:04 ET20002.9502
11:06 ET608682.87
11:08 ET15462.895
11:09 ET93892.9
11:11 ET69422.9
11:13 ET65802.88
11:15 ET13002.895
11:18 ET92762.85
11:20 ET27092.85
11:22 ET124572.8628
11:24 ET66782.9
11:26 ET24002.899
11:27 ET58872.89
11:29 ET1572.9
11:31 ET75412.92
11:33 ET50572.9399
11:36 ET72572.92
11:38 ET23462.9265
11:40 ET40902.9
11:44 ET16002.9
11:47 ET5142.9099
11:51 ET1002.909
11:56 ET9502.9
11:58 ET105862.8606
12:00 ET2502.87
12:02 ET1392.8857
12:05 ET10002.875
12:07 ET5002.8899
12:09 ET9002.86
12:14 ET1002.875
12:16 ET43732.89
12:18 ET34362.9
12:20 ET113772.905
12:21 ET17822.9281
12:23 ET14002.92
12:25 ET10002.93
12:27 ET53142.901
12:34 ET7582.9
12:36 ET18002.91
12:39 ET6502.89
12:41 ET8002.89
12:45 ET1002.9097
12:50 ET30432.91
12:54 ET31002.9123
12:56 ET49002.91
12:57 ET86032.91
12:59 ET10002.895
01:01 ET34002.9041
01:03 ET122942.895
01:06 ET10532.89
01:08 ET10002.895
01:10 ET19002.8999
01:12 ET6002.8905
01:14 ET42342.89
01:15 ET4002.8938
01:17 ET1002.895
01:21 ET4032.895
01:24 ET1722.8946
01:26 ET1002.9
01:28 ET3002.91
01:32 ET14852.91
01:33 ET19452.91
01:35 ET12452.905
01:37 ET29202.9
01:42 ET17002.9073
01:48 ET20002.9
01:51 ET2002.9099
01:53 ET8162.91
01:57 ET5992.895
02:00 ET127232.895
02:02 ET1002.8976
02:04 ET3002.8982
02:08 ET7002.8984
02:09 ET2002.8837
02:11 ET3002.89
02:13 ET1002.88
02:20 ET15302.89
02:22 ET3112.89
02:26 ET4002.8831
02:36 ET13002.86
02:38 ET1222.87
02:40 ET2002.8601
02:42 ET2002.86
02:44 ET1302.8699
02:45 ET2002.865
02:47 ET5002.8699
02:49 ET9002.86
02:56 ET24452.86
03:00 ET4432.8682
03:02 ET8002.87
03:03 ET9002.8698
03:07 ET4002.86
03:09 ET14762.86
03:12 ET2482.865
03:14 ET34662.87
03:16 ET79182.88
03:21 ET2002.88
03:30 ET19012.8896
03:32 ET1352.87
03:34 ET5002.8886
03:38 ET61802.88
03:39 ET7722.89
03:41 ET11092.895
03:43 ET11042.89
03:45 ET19322.9099
03:50 ET9932.9
03:56 ET15912.89
03:57 ET132542.9199
03:59 ET68082.9
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTPST
Tempest Therapeutics Inc
64.4M
-1.6x
---
United StatesAVRO
AVROBIO Inc
64.2M
2.1x
---
United StatesPASG
Passage Bio Inc
64.7M
-0.7x
---
United StatesANTX
AN2 Therapeutics Inc
64.7M
-0.8x
---
United StatesRLYB
Rallybio Corp
64.0M
-0.8x
---
United StatesNVNO
enVVeno Medical Corp
63.6M
-2.8x
---
As of 2024-06-16

Company Information

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Contact Information

Headquarters
2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE, CA, United States 94005
Phone
415-798-8589
Fax
302-655-5049

Executives

Independent Chairman of the Board
Michael Raab
President, Chief Executive Officer, Director
Stephen Brady
Executive Vice President, Chief Medical Officer
Samuel Whiting
Vice President - Strategy and Finance, Corporate Secretary
Nicholas Maestas
Independent Director
Geoffrey Nichol

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$64.4M
Revenue (TTM)
$0.00
Shares Outstanding
22.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-1.67
EPS
$-1.76
Book Value
$1.21
P/E Ratio
-1.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.